Serous ovarian cancers are typically high grade and recur within a short interval. The currently available therapeutic options provide a relatively low response rate and the progress-free survival are short-lived. There is emerging data that CDK4/6 may be effective in metastatic ovarian cancer. This case describes the use of palbociclib after multiple lines of cytotoxic chemotherapy and hormonal therapy. At 30 months upon commencement of palbociclib and letrozole, this patient continues to respond to the treatment radiologically and in the suppression of CA125.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486429 | PMC |
| http://dx.doi.org/10.1016/j.gore.2020.100626 | DOI Listing |
Publication Analysis
Top Keywords
ovarian cancer
8
palbociclib treatment
4
treatment recurrent
4
recurrent ovarian
4
cancer serous
4
serous ovarian
4
ovarian cancers
4
cancers typically
4
typically high
4
high grade
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!